Nerva vs Regulora vs Mahana vs Calm Gut: The 2026 Digital Therapeutics for IBS Comparison Matrix

This is an unaffiliated comparison. No referral relationship, no affiliate arrangement, and no consulting tie with Mindset Health, Metamé Therapeutics, Mahana Therapeutics, or Jayne Corner / The Calm Gut. The goal is a clean read on modality, evidence, regulatory status, cost, and geographic access so you can match the product to the presentation.

A side-by-side of the four apps on the variables that actually drive the choice — regulatory status, mechanism, program structure, price, evidence base, and who each product is genuinely suited to. None of these are head-to-head RCT comparisons; they are the vendors’ published structure alongside the public evidence base.

Pricing and program structures reflect publicly available information at the time of writing (April 2026) and may change. Insurance-mediated prices vary widely. Always confirm current pricing and availability directly with the vendor before purchase.

Nerva is the best-known consumer IBS app globally. Built by Mindset Health, a Melbourne-based digital therapeutics company, it delivers a 6-week self-directed gut-directed hypnotherapy protocol anchored on 42 daily audio sessions of roughly 15 minutes each. The hypnotic framework is derived from the Manchester Protocol — the clinician-delivered gut-directed hypnotherapy programme originally developed and validated at the University Hospital of South Manchester under Peter Whorwell. Nerva adapts that framework to a recorded, app-delivered format rather than replicating it wholesale.

The app sits at roughly $67 USD per year after a 7-day free trial. Users are instructed to listen once daily, with educational modules and a breathing-exercise library interspersed through the protocol. After the 6-week core is complete, the audio becomes available on a maintenance rotation. Nerva is available in app stores globally and does not require a prescription or clinician referral.

The central evidence document is Peters, Gibson, and Halmos (2023, PMID 36661117) in Neurogastroenterology & Motility. It is a retrospective evaluation of 2,843 Nerva users who started the free trial. 1,428 (50%) converted to paid subscription. 253 (9%) completed all 42 sessions. Outcome data were available for 190 of those completers — that is 6.7% of the starting cohort. Among those 190, 64% reported significant symptom improvement. The authors disclose direct financial relationships with Mindset Health, and themselves conclude that “adherence to app-delivered gut-directed hypnotherapy was low” and “a controlled trial comparing face-to-face to app-delivered GDH is indicated.”

An independent analysis (Simicich et al. 2024) reports somewhat higher mid-protocol numbers — 31.7% of paid users reached end-of-program surveys, with an average of 18.22 of 42 sessions completed (about 43%). That picture is still meaningfully below the adherence profile of clinician-delivered Manchester Protocol audits.

Who Nerva fits well: self-motivated users who already maintain a consistent daily health practice, score medium-to-high on hypnotisability (the roughly 70% of adults who respond well to recorded hypnotic induction), have mild-to-moderate IBS symptoms, and have no significant comorbid anxiety, trauma history, or refractory treatment cycle. For that profile, $67 for a structured 6-week GDH protocol is an efficient first move.

Where Nerva is a weak fit: refractory IBS, high-anxiety presentations, users who have already tried a self-directed meditation or hypnosis app without success, or complex gut-brain presentations (pelvic floor, post-infectious, severe bloating). The audio cannot adapt in real time the way a live clinician can, and the Peters 2023 adherence data indicates the format itself is the limiting factor — not the underlying protocol.

Regulora is a Prescription Digital Therapeutic (PDT) developed by Metamé Therapeutics (formerly InFusion) that received FDA De Novo authorisation in November 2021 for the reduction of IBS-related abdominal pain in adults aged 22 and older. It is the first app-delivered gut-directed hypnotherapy product to clear the FDA’s medical-device pathway. Because it is a PDT rather than a wellness app, Regulora requires a US physician prescription and is intended to be used as an adjunct to standard care, not a replacement.

The program is structured as 12 sessions delivered over approximately 3 months, which more closely mirrors the session count of a clinician-delivered Manchester Protocol course than Nerva’s 42-session daily model. Each session blends scripted hypnotic audio with brief educational and skills content. Retail pricing in the US lands around $100 or more depending on pharmacy and insurance pathway, and the practical out-of-pocket cost is highly variable: some commercial insurance and Medicaid plans cover Regulora with prior authorisation, others do not, and Metamé publishes an access program to buffer cash-pay costs.

The evidence base that supported Regulora’s De Novo clearance is sponsor-held clinical trial data, not a large published independent RCT in the peer-reviewed literature at the scale of the Miller 2015 Manchester audit. A pilot randomised controlled trial of app-delivered GDH for IBS has appeared in the GI literature, and additional sponsor-reported trial data was submitted to the FDA as part of the authorisation package. For a careful reader, the honest framing is that Regulora has regulatory-grade evidence — which is a meaningful bar — but the published independent RCT evidence for app-delivered GDH in general remains smaller than the clinician-delivered GDH evidence base.

Who Regulora fits well: US adults with a physician willing to prescribe a PDT, insurance that covers digital therapeutics (or tolerance for an out-of-pocket cash price in the low hundreds), a preference for a shorter session-count protocol, and a preference for gut-directed hypnotherapy over cognitive behavioural therapy.

Where Regulora is a weak fit: non-US patients (Canada, UK, EU, Australia) without cross-border prescription pathways; severe or refractory IBS presentations where clinician adaptation matters; and patients with complex comorbidities that a scripted 12-session audio protocol cannot address session-by-session.

Mahana IBS is a Prescription Digital Therapeutic developed by Mahana Therapeutics that received FDA De Novo authorisation in 2020 for IBS in adults. Unlike Nerva, Regulora, and The Calm Gut — all of which deliver gut-directed hypnotherapy — Mahana IBS delivers cognitive behavioural therapy for IBS (CBT-for-IBS). That is a different mechanism of action. CBT-for-IBS targets the cognitive, behavioural, and emotional patterns that amplify visceral perception and symptom catastrophising; GDH targets the same gut-brain axis through hypnotic down-regulation of visceral sensitivity. Both are in major guideline recommendations for IBS; neither is universally superior.

The Mahana IBS program runs approximately 90 days, with a 6-week structured core covering psychoeducation, relaxation skills, cognitive restructuring, and exposure to previously avoided situations, followed by maintenance modules. Sticker pricing sits around $700 or higher via prescription, with insurance coverage — like Regulora — variable across payers and plans. Most users access Mahana IBS through US prescribers and US pharmacy/PBM pathways.

The underlying evidence is strong. Mahana IBS is an app-packaged version of the telephone-delivered CBT-for-IBS protocol studied in the ACTIB trial (Everitt et al. 2019, Lancet Gastroenterology & Hepatology, PMID 30765267). ACTIB was a pragmatic RCT with 558 participants randomised to telephone-delivered CBT-for-IBS, web-delivered CBT-for-IBS, or treatment as usual. At 12 months, approximately 71% of the telephone CBT arm reported adequate relief, versus a significantly lower response rate in usual care. Effect sizes for IBS-specific symptom severity were meaningful and durable. That is the strongest published RCT evidence base underpinning any of the four products on this page.

The caveat, as with all app-packaged versions of telephone-delivered protocols, is that ACTIB was not a trial of the Mahana IBS app specifically. The app is the commercial vehicle that carries the underlying CBT framework into a self-guided digital format. Whether adherence and response in app form match the telephone-delivered numbers is a separate empirical question; published adherence data on the app in real-world use is limited at this scale compared to the protocol’s telephone form.

Who Mahana IBS fits well: US adults with prescription and insurance access whose personal response profile favours cognitive reframing and skills-based exposure over hypnotic induction. Patients who have previously had success with CBT in any context are a particularly reasonable match. Patients who want an evidence-based non-drug IBS option and are already working with a clinician who can prescribe or refer are in the strongest fit profile.

Where Mahana IBS is a weak fit: users outside the US without prescription access; users who have already tried CBT without meaningful response; users who specifically want a hypnotherapy-based approach; and users whose budget cannot absorb a $700-class price point without insurance coverage.

The Calm Gut (sometimes referred to as “Calm Gut” or marketed through thecalmandhappygut.com) is a consumer-direct gut-directed hypnotherapy program developed by Jayne Corner, an experienced Australian hypnotherapist with a clinical focus on functional GI conditions. Structurally it is the closest direct peer to Nerva: a roughly 6-week self-directed GDH program delivered through daily audio, available as a consumer download, priced in the same general ballpark as Nerva rather than at PDT pricing.

What distinguishes The Calm Gut from Nerva is less about mechanism — both are gut-directed hypnotherapy anchored on the same underlying protocol family — and more about the development pathway and voice. Nerva is a venture-funded digital-therapeutics product with production studio polish. The Calm Gut is a clinician-developed program reflecting the developer’s own in-clinic work with IBS patients. Some users find one induction style works better for them than the other; that is genuinely individual and cannot be predicted in advance.

The evidence base is where The Calm Gut is most different. There is no published randomised controlled trial of the Calm Gut program specifically, and no retrospective adherence evaluation analogous to Peters 2023. That does not mean the program is ineffective — clinician-developed GDH protocols outside the academic RCT ecosystem frequently work well in practice — but users who weight published evidence heavily in their decision-making should be aware of the gap. The underlying modality (gut-directed hypnotherapy) has strong clinician-delivered evidence; the app-delivered version of this particular program does not yet have its own peer-reviewed data.

Who The Calm Gut fits well: users who want a Nerva-alternative GDH experience from a clinician-developed source, who find Nerva’s voice or pacing a poor personal fit, and who are comfortable with a program whose evidence base is clinical- practice-derived rather than RCT-anchored.

Where The Calm Gut is a weak fit: users who require published RCT evidence before adopting a protocol; refractory or complex IBS presentations where an adaptive clinician format is more appropriate; and users who have already tried one consumer GDH app without response — in that case, switching to a different consumer GDH app is unlikely to produce a meaningfully different outcome, and a clinician consultation is the more useful next step.

None of the four products on this page have been compared head-to-head in a randomised controlled trial. That is the single most important fact for consumers to internalise when reading marketing material. Any claim that one of these products is more effective than another is a claim about mechanism (GDH vs CBT, with or without regulatory clearance) rather than a claim that has been tested against its direct competitor in a controlled study.

What does exist is the evidence base for each underlying modality, and the manufacturer-specific data that each vendor has published. The four research anchors that matter most for this comparison are:

Two observations follow from these anchors. First, the mechanisms here are well-evidenced — both gut-directed hypnotherapy and cognitive behavioural therapy for IBS have large RCT literatures supporting clinician- or telephone-delivered formats. Second, the app-delivered translations are a newer and less-studied layer. Peters 2023 is the most thorough adherence look we have for any consumer GDH app, and the adherence picture is the load-bearing caveat for consumer-app DTx generally.

For the two PDTs (Regulora and Mahana IBS), regulatory clearance is a meaningful evidence signal that sits alongside the published literature. FDA De Novo authorisation requires sponsor-held trial data that the FDA has reviewed; it is a higher bar than consumer-app marketing. But it is not a substitute for large independent RCTs published in peer-reviewed journals — it is a different form of evidence scrutiny.

Three of the four products on this page (Nerva, Regulora, Calm Gut) deliver gut-directed hypnotherapy. The fourth (Mahana IBS) delivers cognitive behavioural therapy for IBS. Users often want to know, before committing to any app, whether one modality is fundamentally better than the other. The honest answer is that the RCT literature does not support a clean “one wins” conclusion — both modalities are evidence-based, both are in major guideline recommendations, and neither has been shown superior to the other in a large direct comparison.

Miller 2015 reports 76% response for clinician-delivered GDH on the Manchester Protocol in a 1,000-patient audit, with 5+ year durability. Everitt 2019 reports approximately 71% response at 12 months for telephone-delivered CBT-for-IBS in the 558-patient ACTIB RCT. Those numbers are close enough that, within the confidence intervals of real-world populations, they should be treated as comparable effect sizes. Peters 2016 adds another relevant data point — GDH matched low-FODMAP on GI symptoms and beat it on psychological outcomes, suggesting the mechanism reaches beyond bowel symptoms into the anxiety and quality-of-life dimensions that also drive IBS burden.

Because neither modality is universally superior, the clinically useful question is not “which one wins” but “which one is the better personal match for this patient?” That decision rests on a handful of factors:

• Hypnotisability. Roughly 70% of adults are moderately-to-highly hypnotisable and respond to recorded hypnotic induction. If previous experiences with guided meditation, Yoga Nidra, or hypnotherapy audio have worked for you, GDH is likely a strong fit. If recorded inductions have historically left you unchanged or agitated, CBT-for-IBS may be the more productive starting mechanism.
• Cognitive style. Patients who are strongly analytical, who naturally work through problems via structured reasoning, and who want to understand the catastrophising patterns driving their symptoms often respond particularly well to CBT-for-IBS. Patients who are more somatic-experiential, who describe their symptoms primarily as physical sensations rather than cognitions, often respond particularly well to GDH.
• Comorbidity profile. High-anxiety presentations can be reached through either modality, but clinician-led work is usually more productive than app-delivered either way. Trauma history argues for clinician-led, regardless of modality.
• Prior treatment history. If you have already tried one modality (clinician-delivered or app-delivered) without response, switching to the other mechanism is a reasonable next move. If you have not tried either yet, personal fit factors above should drive the first choice.

The mechanistically-informed way to read the DTx comparison matrix is: Nerva, Regulora, and Calm Gut are alternatives to each other (same mechanism, different delivery formats and regulatory statuses). Mahana IBS is a different branch altogether (CBT mechanism). Choosing Mahana over a GDH app is a choice about which modality to try first; choosing between the three GDH apps is a choice about delivery, evidence anchor, and country of access.

The regulatory category of a digital therapeutic is not a cosmetic detail. A prescription digital therapeutic (PDT) and a consumer wellness app can look nearly identical on a phone screen and still sit on different sides of a real evidence-and-accountability line.

PDTs (Regulora, Mahana IBS) have gone through a formal FDA clearance process — in both cases, the De Novo pathway, which is used when a novel type of device does not have an appropriate predicate. The De Novo pathway requires sponsor-held clinical trial data showing safety and effectiveness for a specific medical indication. FDA reviewers evaluate that data; labelling (the indication for use) is reviewed and constrained; post-market surveillance expectations attach to the product. In exchange, the manufacturer can market the product as a medical device for that indication, physicians can prescribe it, and insurance is legally capable of reimbursing it (though actual reimbursement varies by payer).

Consumer wellness apps (Nerva, Calm Gut) are not medical devices in the regulatory sense. They are marketed as health, wellness, or lifestyle tools. The FDA generally exercises enforcement discretion for this category, meaning consumer wellness apps can make general wellness claims without premarket clearance. They cannot make specific medical claims equivalent to what a PDT is labelled for. The evidence base can still be substantial (as it is for the GDH protocol underlying Nerva), but it was not subject to the same formal regulatory review.

The practical consumer-level differences that follow from this are:

• Evidence floor. PDTs have a minimum evidence bar enforced by the FDA. Consumer wellness apps do not. A PDT is not automatically more effective than a consumer app, but it has been subject to a verification process that the consumer app has not.
• Prescription access. PDTs require a physician prescription. That is both a friction (you need to find a prescribing clinician) and a quality signal (there is a clinical decision layer in front of the product).
• Insurance reimbursement. PDTs can be covered by insurance, at least in principle. In practice, coverage is patchy. FSA and HSA dollars are more commonly usable for PDTs than for wellness apps.
• Labelling discipline. PDT marketing claims are constrained to the FDA-cleared indication. Consumer wellness apps can make more expansive (but less specific) wellness claims.
• Out-of-pocket sticker price. Consumer apps are almost always cheaper at sticker price than PDTs. Whether the cost-per-response is cheaper is a different question, covered below.

For a US reader with prescription access and coverage, the PDT category offers meaningful structural advantages that a consumer app does not replicate. For a reader outside the US, the PDT/consumer distinction is largely academic — Regulora and Mahana are not practically accessible, so the real choice is among the consumer options plus clinician-delivered care.

For Canadian readers — the primary audience of this page — the DTx-for-IBS category looks very different than it does for an American reader looking at the same four apps.

Regulora is US-only at the time of writing. FDA clearance does not grant access in Canada; Health Canada operates its own Medical Devices Regulations framework, and Regulora is not cleared under that pathway. A Canadian patient cannot obtain a Regulora prescription through the Canadian healthcare system. Cross-border workarounds (US telehealth, US-based physician, US pharmacy) exist in principle but are impractical for most patients, are not covered by provincial insurance, and introduce continuity-of-care issues when flare-ups or medication questions arise.

Mahana IBS has primarily operated in the US market with UK availability via partnerships reported in company communications. Canadian availability at scale is not established. Prescription- based access outside the US is limited and depends on partnership arrangements in each market. For the practical Canadian patient, Mahana IBS cannot be assumed accessible.

Nerva and The Calm Gut are consumer wellness apps available globally through the standard mobile app stores. No prescription, no cross-border billing, no regional licensing issues. The trade-off — as discussed above — is that these are not FDA-cleared PDTs and do not have the same evidence floor as Regulora or Mahana. Within the consumer-app tier, they are the most credible and best-developed IBS-specific options.

This means the Canadian IBS-patient decision tree looks like:

• If you want a GDH app: Nerva or The Calm Gut are the two accessible options. The clinician-led alternative is a Canadian-registered hypnotherapist working from the Manchester Protocol framework, either in-person or virtually.
• If you want a CBT-for-IBS app: Mahana IBS is the best-known PDT option but is not reliably accessible in Canada. The alternatives are a Canadian CBT-trained psychologist or therapist, often reimbursed at least partially through private extended health benefit plans, or CBT-oriented self-help workbooks (Toner et al., Craske et al.) that remain in print.
• If you want a PDT specifically: You probably cannot access one in Canada without cross-border friction. The clinician-led path offers a comparable (often higher) evidence base for GDH and is more practically accessible.

Health Canada policy on digital therapeutics is evolving, and both Regulora and Mahana could in principle seek Canadian authorisation in the future. Readers in 2026 or later should verify current availability directly with the vendor before relying on any statement about access.

Sticker price is the number every vendor leads with, because it frames the comparison favourably for whichever product they are selling. Cost-per-response is the number that actually matters when choosing an IBS treatment, because it bundles the probability of the treatment working for you alongside the dollar outlay.

For a consumer GDH app like Nerva, the public adherence data from Peters 2023 lets us sketch a back-of-envelope cost-per-confirmed-responder number. This is a rough directional calculation, not a clinical trial finding:

For comparison, a clinician-delivered 3-session GDH commitment at $220 CAD per session is $660 total. Applying the Miller 2015 76% response rate directly, the rough cost-per-responder works out to $660 / 0.76 ≈ $870 CAD. The clinician-delivered model is more expensive at sticker price than Nerva, but cost-per-responder is comparable — and the underlying evidence base is far larger. The Calm Gut, priced similarly to Nerva, has no published adherence data to ground an analogous calculation, but directional expectations should not differ dramatically from Nerva’s.

For PDTs, the calculation gets more complicated. Sticker price of Regulora (~$100+) and Mahana IBS (~$700+) is the gross number. What the patient actually pays depends on insurance, prior authorisation, and access program enrolment — effective out-of-pocket can range from zero to full cash price. If you assume app-format adherence for PDTs is in a similar band to Nerva’s (this is a conservative assumption; PDT adherence data is less publicly available, and the clinical- oversight layer may improve it), then the effective cost-per-response for a full-cash-pay PDT is meaningfully higher than sticker — perhaps 10–15x, using the same completion math as the Nerva back-of-envelope above. With full insurance coverage, PDT cost-per-response can be dramatically favourable.

The honest summary: sticker price is a poor decision input. Effective cost-per- response, which bundles adherence probability with dollar outlay, is the number to reason about. Consumer GDH apps have a low sticker price and a non-trivial adherence tax. PDTs have a higher sticker price that may or may not be offset by insurance. Clinician-delivered GDH has the highest sticker price of the three tiers but the strongest underlying response rate — which is why, on cost-per-response, it is often surprisingly competitive.

None of the four products on this page are clinician-delivered in real time. Regulora’s 12-session structure comes closest in architecture, but the sessions are still scripted audio rather than live clinical interaction. For a complete picture of the IBS gut-brain-axis treatment landscape in 2026, clinician-led gut-directed hypnotherapy belongs in the frame as a fifth option — even though it is not a DTx app in the product-category sense.

At this practice, the model is a 3-session initial commitment at $220 CAD per session ($660 total) with continuation optional afterward. The protocol follows the Manchester Protocol as a reference framework, adapted session-by-session based on individual response, hypnotisability, and any comorbid anxiety or trauma factors. Virtual and in-person sessions are priced the same, which matters for Canadian readers outside Calgary who can access the protocol through video sessions.

The scenarios where clinician-delivered GDH meaningfully outperforms any app-delivered option are consistent:

• Refractory IBS. The Miller 2015 audit was explicitly a refractory population, and it still produced 76% response. A refractory presentation is also the least likely to complete a self-directed 42-session protocol alone, which is where the Peters 2023 adherence data becomes most costly.
• Comorbid anxiety, panic, or trauma history. Pre-recorded audio cannot notice an abreaction, adjust pacing, or switch induction styles when relaxation triggers hypervigilance. A live clinician can.
• Complex gut-brain presentations. IBS with pelvic floor dysfunction, severe bloating, post-infectious patterns, or significant food-related anxiety benefits from individualised protocols rather than generic audio libraries.
• Prior failed self-directed attempt. If Nerva, Calm Gut, or another hypnosis/meditation app has not worked, repeating the same delivery format is unlikely to produce a different outcome.

Hypnotherapy is complementary care, not a substitute for medical diagnosis or treatment. It is not a regulated health profession in Alberta. A gastroenterologist referral remains the correct first step for new or worsening GI symptoms to rule out structural disease. GDH — whether clinician-delivered or app-delivered — sits downstream of a confirmed functional diagnosis, not upstream of it.

For readers who are not a clean fit for any of the four DTx products on this page — or who have already tried one and not responded — the clinician-led route is often the more efficient next move, both in weeks-to-relief and in overall cost-per-response terms.

Taking all of the above together, the decision about which IBS digital therapeutic — or which non-DTx alternative — is the right starting point comes down to four or five practical filters. In rough priority order:

A useful sanity check on any of these paths is to ask: if this product doesn’t work for me, what does the next step look like? For Nerva or Calm Gut, the next step after a failed trial is typically clinician-led GDH or a CBT-based option. For Regulora, the next step is typically Mahana IBS or clinician-led work. For Mahana, the next step is typically clinician-led CBT or GDH. For clinician-led GDH, the next step is typically a different clinician, a CBT trial, or a more intensive gastroenterology work-up. The exit paths are short; you are not committing to a single tool for life, you are picking the first move in a longer sequence.

The most costly path in practical terms is not picking the “wrong” app first — it is staying on the wrong tool for too long after the first four to six weeks of evidence that it is not moving. Build a clear success metric (symptom diary, IBS-SSS score, days-per-week flares) before starting any of these products, and reassess at a fixed checkpoint.